

Behold the Bili-ruler: A novel, low-cost device for screening neonatal hyperbilirubinemia

May 20 2019



Closeup view of the bili-ruler being used on an infant. Credit: Brigham and Women's Hospital

Neonatal hyperbilirubinemia, commonly known as newborn jaundice, is a condition that affects up to 80 percent of newborns in the first week of life. Severe hyperbilirubinemia (bilirubin levels $>20\text{mg/dL}$) affects an estimated 1 million infants around the world annually. If diagnosed early, severe hyperbilirubinemia is largely treatable with high-intensity phototherapy, resulting in recovery without long-term consequences. If left undiagnosed or untreated, severe hyperbilirubinemia may lead to irreversible brain damage or even death. These complications often arise in low-resource settings; in low- and middle-income countries (LMICs), one-third of infants with extreme hyperbilirubinemia die from a condition that is largely treatable.

But access to treatment itself may not be the primary challenge. One significant barrier to managing hyperbilirubinemia in LMICs is the failure to recognize the severity of the condition before the onset of irreversible symptoms. A team from Brigham and Women's Hospital recently reported the creation and validation of a novel tool, the Bili-ruler, designed for use by frontline health workers to screen for hyperbilirubinemia in [low-resource settings](#). The findings are published in *Pediatrics*.

"In low-income settings, many people don't have access to very basic diagnostics, medications and interventions that could prevent a large burden of neonatal morbidity and mortality," said lead author Anne CC Lee, MD, MPH, a pediatrician, director of the Brigham Global Newborn Health Lab and principal investigator of the project. "Improving early recognition and care seeking for potentially serious newborn illness is a first step."

The first low-cost screening tool for jaundice was the Gosset icterometer developed in the 1950s. This device comprised five shades of yellow and presented good correlation with serum bilirubin concentrations; however, it was developed using robbialac paint which led to a lack of

color standardization and was never widely adopted. Currently, in high-income settings, there are transcutaneous bilirubin instruments, but these cost over \$7,000 and are not affordable in most low-income settings.

"Ultimately, if the baby is not diagnosed or is diagnosed too late, there is very little that can be done before the effects are permanent," said co-author Lian Folger, a program coordinator at the Global Newborn Health Lab.

To address this barrier of illness recognition, the team designed the Bili-ruler to improve the identification of clinically severe hyperbilirubinemia in low-resource settings. As its name suggests, the Bili-ruler is a portable, handheld "ruler" to measure the degree of newborn jaundice, using six color strips arranged in a stepwise gradient of increasing yellow hue. The colors were developed using advanced digital color processing of images of infants with different levels of hyperbilirubinemia.

To assess for jaundice, the Bili-ruler is pressed against the infant's skin, and the underlying skin tone is visualized through a circular window enclosed by a uniform color strip. This process is repeated for all six colors, and the user chooses the score which corresponds to the color that most closely matches the underlying skin tone. The team went through many iterations of the design of the device and collaborated with groups at MIT that specialize in visual design.

To validate the Bili-ruler across diverse populations, the research team recruited a total of 790 newborns from the Brigham and its partner institution, the Sylhet Osmani Medical College Hospital (SOMCH) in Sylhet, Bangladesh. Newborns were eligible for inclusion if they were

hyperbilirubinemia (2019, May 20) retrieved 19 September 2024 from
<https://medicalxpress.com/news/2019-05-bili-ruler-low-cost-device-screening-neonatal.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.